nirogacestat,lenalidomide,teclistamab,daratumumab,pomalidomide,bortezomib
takeda,springworks therapeutics,janssen,genmab,bms
['toci', 'majestec-2', 'bet', 'mmsm', 'lenalidomide', 'daratumumab', 'teclistamab', ' dara ', ' lena', 'dexamethasone', 'tocilizumab', 'majestec,(-majestec-1),(-majestec1),(-majestec 1),(-majestec-3),(-majestec3),(-majestec 3),(-majestec-i),(-majestec i),(-majesteci)', 'anakinra']
rub some drt on it. majestec-2 with dara/len/tec. orr 93.5% in a less refractory population with high rates of cr (55%). no data on mrd negativity among the cr population. but definitely makes a case for combination strategies for teclistamab. #ash22 #mmsm 
Asst Professor at University of Chicago, specializing in (vanquishing) plasma cell disorders. I tweet about: Myeloma & MRD. https://t.co/mPeWg1QRrW